NCT03010475View on ClinicalTrials.gov

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 5, 2017

Primary Completion Date

June 4, 2017

Study Completion Date

August 9, 2017

Conditions
DiabetesHealthy
Interventions
DRUG

Furosemide

Oral administration A total of three single doses.

DRUG

Rosuvastatin

Oral administration. A total of three single doses.

DRUG

SNAC

Oral administration. A total of five single doses.

DRUG

Semaglutide

Oral administration. Once daily.

Trial Locations (1)

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY